Not sure if this is a GOOD deal partnershipwise bu

Not sure if this is a GOOD deal partnershipwise but as it has not yet affected the stock PPS much but if IPIX were to get one like it think it for just one of its drugs seems to me it would put IPIX in a much firmer future financial position.

EXAMPLE HERE is on PLX , also a small development stage drug company. Think IPIX can do better though

Protalix BioTherapeutics Enters into an Exclusive Ex-US Partnership with Chiesi Farmaceutici for the Development and
Commercialization of PRX-102 (pegunigalsidase alfa) for the Treatment of Fabry Disease
Protalix grants Chiesi Ex-US rights to PRX-102, a chemically modified version of the recombinant protein alphaGalactosidase-A
protein
Protalix to receive $25 million upfront, an additional up to $25 million in development costs and an additional up to $320
million in potential regulatory and commercial milestone payments
Protalix to receive tiered royalties ranging from 15% to 35% on net sales
CARMIEL, Israel, October 18, 2017 -- GlobeNewswire /Protalix BioTherapeutics, Inc. (NYSE AmericanLX, TASELX), a
biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins
expressed through its proprietary plant cell-based expression system, ProCellEx®, today announced an Ex-US license and
collaboration agreement with Chiesi Farmaceutici S.p.A., or Chiesi, for pegunigalsidase alfa, or PRX-102, the Company’s
chemically modified version of the recombinant protein alpha-Galactosidase-A protein that is currently being evaluated
in phase III clinical trials for the treatment of Fabry disease. PRX-102 has demonstrated a significantly enhanced
circulatory half-life and higher enzyme activity in the target organs affected by Fabry disease when compared to
currently available versions of the molecule, and strong positive safety and efficacy data from its completed phase I/II
clinical trial.
“We are pleased to partner with Chiesi, an international privately-held company with more than 80 years of experience
and a strong focus on the development and commercialization of innovative medicines with commercial presence in
virtually all markets outside the United States,” commented Moshe Manor, Protalix’s President and Chief Executive
Officer. “The $50 million commitment made by Chiesi before any of our ongoing phase III clinical trial results read-out is
not only a significant non-dilutive cash infusion for us, it also represents Chiesi’s commitment to the Fabry market in
general and our PRX-102 program in particular. With this transaction, we have secured significant and important
funding while maintaining full rights to PRX-102 in the U.S. market.”
Under the terms of the agreement, Protalix has licensed PRX-102 to Chiesi for all markets outside of the United States,
and Protalix will receive an upfront payment of $25 million from Chiesi and additional payments of up to $25 million in
development costs, capped at $10 million per year. Protalix is also eligible to receive an additional up to $320 million, in
the aggregate, in regulatory and commercial milestone payments, and tiered royalties ranging from 15% to 35% on net
sales. Protalix will continue to be the manufacturer of PRX-102 for clinical development purposes and commercial
purposes after marketing approvals.
“With revenues of approximately $1.8 billion, the Chiesi Group is among the top 50 pharmaceutical companies in the
world. By combining the respective strengths of Chiesi and Protalix to advance PRX-102, we look forward to bringing a
novel, differentiated therapeutic option to patients suffering from Fabry disease who have a true need for an alternative
treatment with an improved safety and efficacy profile,” said Ugo Di Francesco, Chiesi’s CEO. “PRX-102 complements
our existing product portfolio in rare diseases and underscores our commitment to bringing novel therapeutics to
patients across the globe.”
Additional details regarding the collaboration can be found in Protalix's Form 8-K to be filed with the Securities and
Exchange Commission.
About Protalix BioTherapeutics, Inc.
Protalix is a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic
proteins expressed through its proprietary plant cell-based expression system, ProCellEx®. Protalix’s unique expression
system presents a proprietary method for developing recombinant proteins in a cost-effective, industrial-scale manner.
Protalix’s first product manufactured by ProCellEx, taliglucerase alfa, was approved for marketing by the U.S. Food and
Drug Administration (FDA) in May 2012 and, subsequently, by the regulatory authorities of other countries. Protalix has
licensed to Pfizer Inc. the worldwide development and commercialization rights for taliglucerase alfa, excluding Brazil,
where Protalix retains full rights. Protalix’s development pipeline includes the following product candidates:
pegunigalsidase alfa, a modified version of the recombinant human alpha-GAL-A protein for the treatment of Fabry
disease; OPRX-106, an orally-delivered anti-inflammatory treatment; alidornase alfa for the treatment of Cystic Fibrosis;
and others.
About Chiesi Farmaceutici S.p.A.
Based in Parma, Italy, Chiesi Farmaceutici is an international research-focused Healthcare Group, with over 80 years of
experience in the pharmaceutical industry. Chiesi researches, develops and markets innovative drugs in the respiratory
therapeutics, specialist medicine and rare disease areas. Its R&D organization is headquartered in Parma (Italy), and
integrated with 6 other key R&D groups in France, the USA, the UK, Sweden and Denmark to advance Chiesi's pre-clinical,
clinical and registration programmes. Chiesi employs nearly 5,000 people. For more information, visit www.chiesi.com.